
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC has demonstrated a robust financial outlook, bolstered by a 95% probability of success for its proprietary psilocybin formulation, COMP360, following positive 6-week top-line data from the COMP005 study. The data indicated a clinically significant -3.6-point placebo-adjusted reduction on the MADRS scale, underscoring COMP360's potential effectiveness in treating treatment-resistant depression (TRD). Additionally, the company’s planned low-frequency dosing regimen for COMP360, requiring only 2-4 sessions per year, may increase its competitive edge over existing therapies, further enhancing its market prospects and appeal to patients and healthcare providers alike.
Bears say
Compass Pathways PLC has recently encountered challenges, as indicated by unexpected higher research and development (R&D) expenses related to advancing its COMP360 Phase 3 clinical trials, leading to a slight decrease in cash and cash equivalents from prior estimates. Potential competitive pressures could arise if rival companies produce compelling data in similar therapeutic areas, which may negatively affect the stock's valuation. Additionally, a strategic reorganization that resulted in decreased personnel has not fully alleviated financial strains, suggesting ongoing volatility and uncertainties surrounding the company's future performance and market positioning.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares